Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: EU Industry Claims ‘Undeniable’ Role Of IP, UK Targets Younger At-Risk Groups For Vaccination

Executive Summary

Draft EU legislation on tackling cross-border health threats has taken another step forward, as health authorities say the Delta variant of the SARS-CoV-2 virus will be the “globally dominant strain” over the coming months.

You may also be interested in...



EU Politicians Want Stronger Role For European Medicines Agency In Health Risk Assessment

Legislation that will help to build a future “European Health Union” is making its way through the EU legislative process. It includes a greater role for EU health agencies in making preparations for future health emergencies.

EU Health Ministers Back Stronger Pandemic Role For EMA

Proposals for establishing a ‘European Health Union’ include measures to give the EU regulator more say in monitoring and mitigating potential and actual shortages of drugs and devices in the event of serious public health crises.

Coronavirus Notebook: EMA OKs More Vaccine Production Plants, WHO Sounds Alert Over Africa

Vaxzevria should not be given to people who have had capillary leak syndrome, the EU regulator says. The G7 leaders have made big pledges on vaccine donations, and international regulatory bodies have issued a guide to shoring up confidence in vaccination.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144700

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel